Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL)

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRicha ManwaniACAkhilesh ChamediyaAWAshutosh Wechalekar

Discussion

Loading...

Member takes

Overview

Phase 1b/2 trial demonstrates safety and efficacy of AZD0120 in relapsed light chain amyloidosis, suggesting new treatment options.

Key Points

  • To evaluate the safety and efficacy of AZD0120 in adult participants with relapsed or refractory light chain amyloidosis.
  • Open-label, multicenter, global, non-randomized study design
  • Participants aged ≥18 with confirmed light chain amyloidosis
  • Evaluating various dose levels of AZD0120
  • Primary endpoint: proportion of patients achieving hematologic complete response
  • Secondary endpoints include overall survival and event-free survival
  • AZD0120 aimed to show superior efficacy compared to single-target CAR-T therapies
  • Safety and pharmacodynamics will be characterized throughout the trial
  • The study targets a median follow-up duration of 15 years for comprehensive assessment

Cite This Study

Manwani et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e32dhttps://doi.org/10.1182/blood-2025-8236
View Full Paper
Ask AI
Bookmark
Share